Segall Bryant & Hamill LLC Sells 19,781 Shares of Galapagos NV (NASDAQ:GLPG)

Segall Bryant & Hamill LLC trimmed its stake in shares of Galapagos NV (NASDAQ:GLPG) by 2.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 685,867 shares of the biotechnology company’s stock after selling 19,781 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Galapagos were worth $18,861,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of GLPG. R Squared Ltd bought a new position in shares of Galapagos during the 4th quarter worth approximately $26,000. GAMMA Investing LLC raised its stake in Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 974 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Galapagos by 5.9% during the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company’s stock valued at $711,000 after acquiring an additional 1,431 shares during the period. QRG Capital Management Inc. boosted its stake in shares of Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 1,866 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in shares of Galapagos by 31.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company’s stock worth $1,352,000 after purchasing an additional 11,777 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors.

Galapagos Trading Down 1.6 %

Shares of GLPG stock opened at $25.53 on Wednesday. Galapagos NV has a 1 year low of $22.36 and a 1 year high of $33.00. The firm’s 50 day moving average is $24.97 and its 200-day moving average is $26.98.

Analyst Ratings Changes

GLPG has been the topic of a number of recent analyst reports. Barclays restated an “underweight” rating on shares of Galapagos in a research report on Thursday, January 23rd. TD Cowen lowered Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Finally, Morgan Stanley downgraded Galapagos from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $31.00 to $22.00 in a research report on Friday, February 14th. Five research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Based on data from MarketBeat, Galapagos has a consensus rating of “Reduce” and a consensus target price of $26.75.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.